|Free Dividend Report|
|Stock Splits Calendar|
|COGT Stock Split History|
|Preferred Stock Newsletter|
|COGT Options Chain|
|COGT Message Board|
Cogent Biosciences (COGT) has 1 split in our COGT split history database. The split for COGT took place on November 09, 2020. This was a 1 for 4 reverse split, meaning for each 4 shares of COGT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.
When a company such as Cogent Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the COGT split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cogent Biosciences shares, starting with a $10,000 purchase of COGT, presented on a split-history-adjusted basis factoring in the complete COGT split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-38.93%|
|About Cogent Biosciences|
|Cogent Biosciences is a biopharmaceutical company focused on developing curative cell therapies for solid tumors. Co.'s proprietary technology includes its Bolt-On Chimeric Receptor platform, designed to discover bolt-on transgenes to improve the functionality of engineered T cells and overcome resistance of the solid tumor microenvironment to T cell attack. Co. has also developed product candidates using its proprietary technology, Antibody-Coupled T cell Receptor, an autologous engineered T-cell investigational therapy that is designed to combine the cell-killing ability of T cells and the tumor-targeting ability of co-administered antibodies to exert antitumor immune responses. According to our COGT split history records, Cogent Biosciences has had 1 split.|
|COGT Split History Table|
|11/09/2020||1 for 4|
|Industrials Stock Splits|
|COGT is categorized under the Industrials sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: COGT shares outstanding history